Eli Lilly has unveiled promising data from its Phase IIIb SURMOUNT-5 study, showing that its weight loss treatment, Zepbound (tirzepatide), outperforms Novo Nordisk’s Wegovy (semaglutide) in terms of weight reduction.…
Applied Therapeutics, the biopharmaceutical company focused on developing treatments for rare diseases, recently received a warning letter from the U.S. Food and Drug Administration (FDA) following concerns raised about the…
BeiGene a global leader in oncology, has announced a new partnership with the CLL Society, the premier authority for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) cancer patients.…
If public transportation is your ticket to holiday cheer, it’s vital to take precautions to avoid illness while en route. Hand hygiene is your first line of defense during the…
The World Health Organization (WHO) has granted prequalification to the Xpert® MTB/RIF Ultra molecular diagnostic test, making it the first tuberculosis (TB) diagnostic and antibiotic susceptibility test to meet WHO’s…
Teva Pharmaceutical Industries has announced encouraging results from its Phase 3 SPACE study, which evaluated the efficacy and safety of AJOVY (fremanezumab) for preventing episodic migraines in children and adolescents…
Novo Nordisk has announced that 13 abstracts from its research will be presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Diego,…
CVS Health has announced two key leadership appointments to further strengthen its Pharmacy and Consumer Wellness division. Len Shankman has been appointed as president of Pharmacy and Consumer Wellness (PCW),…
Merck known as MSD outside the U.S. and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) for the treatment…
COUR Pharmaceuticals, a biotech company based in Chicago, has entered into a significant partnership with Roche’s Genentech to develop and commercialize treatments for an undisclosed autoimmune disease. This collaboration follows…
Intra-Cellular Therapies has submitted a supplemental New Drug Application (sNDA) to the FDA for its drug Caplyta (lumateperone) for the treatment of Major Depressive Disorder (MDD) in adults. The approval…
Ipsen and Biomunex Pharmaceuticals have entered into an exclusive global licensing agreement for BMX-502, a promising bispecific antibody designed to target and activate Mucosal-Associated Invariant T cells (MAIT cells) to…